NervGen Pharma Corp. NGEN
1.33 USD +0.01 (+0.76%)
At close·Nov 6, 2026, 5:32 PM EST
1.31 -0.02 -1.50%
After hours · Nov 6, 5:32 PM ET
- YTD
- -76.25%
- 1 year
- -42.17%
Altman Z-Score
-1.30 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
D+1 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
P/E -12.6×
P/S 0.0×
P/B 160×
P/FCF -28.5×
EV/EBITDA -94.4×
EV/Sales 0.0×
FCF Yield -3.5%
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
ROE -1268.9%
ROIC -719.6%
ROA -190.1%
Revenue 0.0%
Operating Income -0.7%
EPS (diluted) -69.4%
Free Cash Flow -15.9%
Current Ratio 1.2×
Quick Ratio 1.2×
Debt / Equity 0.0×
Net Debt / EBITDA 3.9×
Interest Coverage 0.0×
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2025-12-31
